accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis (REBOOT-PARADOX)

Optimal Medical Treatment With or Without Valve Repair in Patients With Symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis - a Multi-center, Randomized Comparison

Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.

Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.

REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Baden-Wurttemberg
      • Tübingen, Baden-Wurttemberg, Germany, 72076
        • Universitätsklinikum Tübingen
    • Bavaria
      • München, Bavaria, Germany, 80636
        • Deutsches Herzzentrum München
      • München, Bavaria, Germany, 81377
        • Klinikum der Universität München-Großhadern
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Germany, 20246
        • Universitäres Herz- u. Gefäßzentrum Hamburg
    • Hesse
      • Bad Nauheim, Hesse, Germany
        • Kerckhoff-Klinik GmbH
    • Lower Saxony
      • Bad Bevensen, Lower Saxony, Germany, 29549
        • Herz- und Gefäßzentrum Bad Bevensen
    • Mecklenburg-Vorpommern
      • Rostock, Mecklenburg-Vorpommern, Germany, 18057
        • Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie
    • North Rhine-Westphalia
      • Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545
        • Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen
      • Cologne, North Rhine-Westphalia, Germany, 50937
        • Herzzentrum der Universität Köln
    • Rhineland-Palatinate
      • Ludwigshafen am Rhein, Rhineland-Palatinate, Germany
        • Klinikum der Stadt Ludwigshafen a. Rh.
    • Saxony
      • Leipzig, Saxony, Germany
        • Herzzentrum Leipzig
    • Schleswig-Holstein
      • Bad Segeberg, Schleswig-Holstein, Germany
        • Segeberger Kliniken, Herzzentrum
      • Milan, Italy, 20089
        • Humanitas Mirasole S.P.A
      • Pisa, Italy, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Zurich, Switzerland, 8091
        • Universitätsspital Zürich, Universitätres Herzzentrum Zürich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years
  • I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient < 40 mmHg and stroke volume index (SVI) < 35ml/m2
  • I3. Left ventricular ejection fraction ≥ 50%
  • I4. MDCT aortic valve calcium score men > 2000AU, women > 1200AU OR the likelihood criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age < 70 yrs., AVS < 0.8 cm2; SVI < 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV longitudinal function without other reason)
  • I5. Heart team agrees on eligibility for TAVR
  • I6. Written informed consent
  • I7. Negative pregnancy test in women with childbearing potential

Exclusion Criteria:

  • E1. Hemodynamic instability
  • E2. Cardiogenic shock
  • E3. Pre-existing mechanical or bio-prosthetic valve in any position
  • E4. Concomitant severe valvular heart disease
  • E5. Pre-existing or active endocarditis
  • E6. Need for heart surgery due to other conditions
  • E7. Aortic valve is congenital unicuspid or congenital bicuspid
  • E8. Hypertrophic cardiomyopathy with or without obstruction
  • E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • E10. Acute myocardial infarction within 1 month before intended AS-treatment
  • E11. Renal replacement therapy
  • E12. Estimated life expectancy < 24 months (730 days) due to carcinomas end stage liver disease or renal disease
  • E13. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  • E14. Patient refuses aortic valve repair

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: TAVR Group

Patients will be treated by transcatheter aortic valve repair (TAVR).

Repair of defective aortic valve by microsurgical Intervention.

No Intervention: Medical Treatment Group

Patients will receive optimal medical treatment alone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to death
Time Frame: 24 months after last-patient-in

All-cause mortality

24 months after last-patient-in

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular mortality
Time Frame: 5 years after index treatment

Death because of cardiovascular events

5 years after index treatment
Re-hospitalization due to heart failure
Time Frame: 5 years after index treatment

Number of hospital stays after randomization

5 years after index treatment
Incidence of neurological events - incidence of strokes
Time Frame: 5 years after randomization

Number of strokes

5 years after randomization
Incidence of neurological Events - incidence of transient ischaemic attacks
Time Frame: 5 years after randomization

Number of transient ischaemic attacks

5 years after randomization
Cardiac functionality - left ventricular function
Time Frame: 5 years after randomization

Echocardiographic measurement of left ventricular ejection fraction in %

5 years after randomization
Cardiac functionality - aortic valve hemodynamics
Time Frame: 5 years after randomization

Measurement of aortic pressure in mmHg

5 years after randomization
Patients' quality of life
Time Frame: 5 years after randomization

EQ5D-score in %

5 years after randomization
Device reliability
Time Frame: 5 years after randomization

Number of reinterventions (TAVR arm only)

5 years after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Steffen Massberg, Prof. Dr., University Clinic Munich

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 3, 2019

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

February 27, 2019

First Submitted That Met QC Criteria

March 4, 2019

First Posted (Actual)

March 5, 2019

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • REBOOT-PARADOX

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.